The role of NFкB regulated pathways in maintaining and promoting hypoxia, inflammation and stemness in cancer cells has been an area of significant scientific interest and many NFкB/HIF-1α inhibitors are under clinical cancer trials [48–51]. The gene discussed is HIF1A; the disease is cancer.